Company: INMB
Filing Date: 2025-02-12
Form Type: 8-K
Source: 0001213900-25-012870
Chunk: 0

Company: Inmune Bio, Inc.
Filing Date: 2025-02-12
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01. Other Events.

On February 12, 2025,
INmune Bio Inc. (the “ Company”), issued a press release announcing the completion of the third and highest dose cohort of
the Phase I portion of the Company’s natural killer cell therapy, INKmune™, in a Phase I/II trial for men with metastatic
castration-resistant prostate cancer, allowing opening of the Phase II high dose cohort.

A copy of the Company’s press release is
attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial statements and Exhibits